Literature DB >> 224848

Topical antibiotic therapy of Pseudomonas aeruginosa keratitis.

A Kupferman, H M Leibowitz.   

Abstract

The in vivo antibacterial effectiveness in the rabbit cornea of several commercially available ophthalmic antibiotic preparations was determined against a single strain of Pseudomonas aeruginosa isolated from a human corneal ulcer. Each antibiotic was instilled topically at hourly intervals, and the number of residual viable organisms in the cornea subsequently was ascertained. In vivo measurements correlated well with in vitro data and with generally held clinical impressions. Three antibiotics, gentamicin sulfate, polymyxin B sulfate, and colistin sulfate, suppressed corneal growth of P aeruginosa in commercially available concentrations. Gentamicin was slightly more effective than polymyxin B; both drugs were substantially more effective than colistin. Formulations of gentamicin and polymyxin B containing approximately four times the quantity of drug found in commercial preparations eliminated this P aeruginosa strain from the cornea much more rapidly than did the commercial preparations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 224848     DOI: 10.1001/archopht.1979.01020020267016

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Microbial keratitis: what's the preferred initial therapy? View 1: corneal scraping and combination antibiotic therapy is indicated.

Authors:  R Mills
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

Review 2.  Experimental Pseudomonas keratitis.

Authors:  R A Hyndiuk
Journal:  Trans Am Ophthalmol Soc       Date:  1981

Review 3.  Treatment of bacterial ulcers of the cornea in the rabbit: a comparison of administration by eye drops and subconjunctival injections.

Authors:  J Baum
Journal:  Trans Am Ophthalmol Soc       Date:  1982

Review 4.  Foundational concepts in the biology of bacterial keratitis.

Authors:  Lawson Ung; James Chodosh
Journal:  Exp Eye Res       Date:  2021-06-05       Impact factor: 3.770

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.